GSK Asks FDA To Mull Expansion Of NRT Indications
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Consumer Health division calls on FDA to consider expanding indications and use of over-the-counter nicotine replacement therapies to maximize the public health benefit
You may also be interested in...
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication
CDER-Tobacco Center Joint Meeting Could Signal Talks On NRT Indications
FDA's work to implement its tobacco control authorities includes planning a joint meeting of its drug and tobacco centers to address issues such as the extended use of nicotine replacement therapy
NRT Petition Calls On FDA To Greatly Expand Indications, Availability
FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability